These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

823 related articles for article (PubMed ID: 25752738)

  • 41. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
    Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans.
    Atiee G; Lasseter K; Baughman S; McCullough A; Collis P; Hollister A; Hernandez J
    J Clin Pharmacol; 2012 Sep; 52(9):1410-9. PubMed ID: 21960669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.
    McCullers JA
    J Infect Dis; 2004 Aug; 190(3):519-26. PubMed ID: 15243927
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
    Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
    Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
    Barroso L; Treanor J; Gubareva L; Hayden FG
    Antivir Ther; 2005; 10(8):901-10. PubMed ID: 16430195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pulmonary immunostimulation with MALP-2 in influenza virus-infected mice increases survival after pneumococcal superinfection.
    Reppe K; Radünzel P; Dietert K; Tschernig T; Wolff T; Hammerschmidt S; Gruber AD; Suttorp N; Witzenrath M
    Infect Immun; 2015 Dec; 83(12):4617-29. PubMed ID: 26371127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques.
    Kitano M; Itoh Y; Kodama M; Ishigaki H; Nakayama M; Ishida H; Baba K; Noda T; Sato K; Nihashi Y; Kanazu T; Yoshida R; Torii R; Sato A; Ogasawara K
    Antimicrob Agents Chemother; 2011 Nov; 55(11):4961-70. PubMed ID: 21844317
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection.
    Cho J; Yi H; Jang EY; Lee MS; Lee JY; Kang C; Lee CH; Kim K
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):298-304. PubMed ID: 29017920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection.
    Boianelli A; Sharma-Chawla N; Bruder D; Hernandez-Vargas EA
    Front Cell Infect Microbiol; 2016; 6():60. PubMed ID: 27379214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Flavonoids from Houttuynia cordata attenuate H1N1-induced acute lung injury in mice via inhibition of influenza virus and Toll-like receptor signalling.
    Ling LJ; Lu Y; Zhang YY; Zhu HY; Tu P; Li H; Chen DF
    Phytomedicine; 2020 Feb; 67():153150. PubMed ID: 31958713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Loss of T-bet confers survival advantage to influenza-bacterial superinfection.
    Er JZ; Koean RAG; Ding JL
    EMBO J; 2019 Jan; 38(1):. PubMed ID: 30322895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous peramivir for treatment of influenza in hospitalized patients.
    Ison MG; Fraiz J; Heller B; Jauregui L; Mills G; O'Riordan W; O'Neil B; Playford EG; Rolf JD; Sada-Diaz E; Elder J; Collis P; Hernandez JE; Sheridan WP
    Antivir Ther; 2014; 19(4):349-61. PubMed ID: 23985625
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of TheraMax on influenza virus infections in cell culture and in mice.
    Smee DF; Hurst BL; Wong MH
    Antivir Chem Chemother; 2011 Jul; 21(6):231-7. PubMed ID: 21730370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.
    Haasbach E; Pauli EK; Spranger R; Mitzner D; Schubert U; Kircheis R; Planz O
    Antiviral Res; 2011 Sep; 91(3):304-13. PubMed ID: 21777621
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan.
    Takashita E; Kiso M; Fujisaki S; Yokoyama M; Nakamura K; Shirakura M; Sato H; Odagiri T; Kawaoka Y; Tashiro M
    Antimicrob Agents Chemother; 2015 May; 59(5):2607-17. PubMed ID: 25691635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Total alkaloids from Alstonia scholaris inhibit influenza a virus replication and lung immunopathology by regulating the innate immune response.
    Zhou HX; Li RF; Wang YF; Shen LH; Cai LH; Weng YC; Zhang HR; Chen XX; Wu X; Chen RF; Jiang HM; Wang C; Yang M; Lu J; Luo XD; Jiang Z; Yang ZF
    Phytomedicine; 2020 Oct; 77():153272. PubMed ID: 32702592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
    Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
    J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection.
    Pascua PNQ; Mostafa HH; Marathe BM; Vogel P; Russell CJ; Webby RJ; Govorkova EA
    Sci Rep; 2017 Aug; 7(1):7345. PubMed ID: 28779075
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.
    McCullers JA; Bartmess KC
    J Infect Dis; 2003 Mar; 187(6):1000-9. PubMed ID: 12660947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.